Please login to the form below

Not currently logged in
Email:
Password:

GS-5806

This page shows the latest GS-5806 news and features for those working in and with pharma, biotech and healthcare.

Gilead's RSV drug clears mid-stage trial

Gilead's RSV drug clears mid-stage trial

Gilead's RSV drug clears mid-stage trial. Late-stage data demonstrates GS-5806 is effective in treating the infection. ... The company presented the results of a study of GS-5806, an orally-active RSV fusion inhibitor, showing that it was able to limit

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics